SoftOx Solutions AS (SoftOx), a clinical-stage biopharmaceutical company based
in Norway, announces that it has published its Annual Report for 2022. The Board
of Directors has approved the 2022 annual financial statements prepared in
accordance with the Norwegian Accounting Act and accounting standards and
practises generally accepted in Norway. The financial statements are in
accordance with the Q4 reporting published on 15th February 2023. These
documents are also available at the Company's website,
https://soft-ox.com/press-releases-updates/. 

For further information, please contact: 
Geir Almås, CEO of SoftOx Solutions AS, or Ingrid Juven, COO at SoftOx Solutions
AS 
Mail: ir@soft-ox.com Phone: Front Desk: (+47) 948-59-599 
About SoftOx Solutions AS SoftOx Solutions AS (SoftOx, listed on Euronext Growth
Oslo) is a Norwegian medtech/biotech company based in Oslo with the aim of
helping to combat major threats to human health, namely the emergence of
antimicrobial resistance (AMR), biofilm infections in chronic wounds and the
spread of viruses. For more information on SoftOx, visit www.soft-ox.com